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Abstract Here we report the cloning of a gene encoding a new 
member of the superfamily of G protein-coupled receptors. The 
gene encodes a protein of 365 amino acids closely resembling two 
recently cloned nucleotide binding receptors, called P2u and P2Y 
purinoceptors (71% and 49% sequence identity within the 
transmembrane domains, respectively). Our studies show that 
this new putative purinoceptor (designated P2P) is encoded by an 
introuless single copy gene that is exclusively expressed in 
pancreas, in contrast o the P2u and the P2Y purinoceptors which 
are widely distributed throughout he periphery. The identifica- 
tion of a pancreas-specific human putative P2 purinoceptor 
makes it attractive to speculate that the reported actions of 
ADP/ATP analogues in pancreas on insulin secretion are 
mediated through this receptor. 
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ture, a hallmark of receptors that couple to guanine nucleo- 
tide binding (G) proteins [18]. In this study we have exploited 
the structural resemblance among receptors that couple to G- 
proteins to clone a novel member of the P2 purinoceptor 
family. Using polymerase chain amplification of genomic 
DNA with degenerate primers corresponding to conserved 
transmembrane domains of previously cloned serotonin recep- 
tors [6,17], we identified a novel P2 purinoceptor. Here we 
report the genomic cloning and characterization of a gene 
encoding a new P2 purinoceptor subtype that is exclusively 
expressed in pancreas. The identification of a pancreas-specific 
P2 purinoceptor is especially of interest in view of the reported 
actions of ADP analogues on insulin secretion via a pharma- 
cologically defined P2-1ike purinoceptor in pancreas 
[5,6,21,221. 
2. Materials and methods 
I. Introduction 
Nucleotides uch as ATP, ADP, and UTP act as intercel- 
lular neurotransmitters and exert a broad range of physio- 
logical responses in both the central and peripheral nervous 
system, such as insulin secretion, vasodilatation, platelet ag- 
gregation, wound healing, and transepithelial ion transport 
[1-6]. These effects are mediated via activation of extracellular 
membrane receptors, known as P2 purinoceptors, to distin- 
guish them from the P1 purinoceptors that bind adenosine 
(reviewed in [7,8]). The existence of multiple peripheral pur- 
inoceptors may help account for some of the complex physio- 
logical responses thought o be brought about by extracellular 
nucleotides. At least five P2 purinoceptor subtypes (P2x, P2Y, 
Pzt~,, PZT, P2z) have been identified on the basis of pharma- 
cological criteria, the most important of which is their rank 
order of potency for a number of reference compounds [8]. 
The classification of Pz purinoceptor subtypes, however, is 
seriously hampered by the lack of selective (ant)agonists as 
well as the chemical instability of some of the nucleotide li- 
gands [8]. 
The recent cloning of three members of the P2 purinoceptor 
family has considerably improved our understanding of the 
structure and mechanism of activation of purinoceptors [7,9- 
14]. Moreover, the elucidation of the protein structure has 
added an additional criterion to allow adequate receptor clas- 
sification. Whereas the predicted amino acid sequence of the 
P2x purinoceptor shows resemblance to members of the li- 
gand-gated ion channels, the cloned P2u and P2Y purinoceptor 
showed the presence of a putative seven-transmembrane struc- 
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2.1. General methods 
All general recombinant DNA procedures were performed as de- 
scribed by Sambrook et al. [15]. Restriction endonucleases were pur- 
chased from Pharmacia. Radiolabelled nucleotides were from DuPont 
(NEN). 
2.2. PCR amplification 
Total human genomic placenta DNA, purchased from Clontech 
Laboratories (Palo Alto, CA, USA), was used as a template for poly- 
merase chain (PCR) amplification with a set of degenerate oligonu- 
cleotide primers corresponding to conserved sequences of the third 
and sixth transmembrane domains of known G-protein-coupled ser- 
otonin (5-HT) receptors. One of the primers contained inosine as base 
substitute to avoid too much sequence degeneracy following the ori- 
ginal paper of Libert et al. [16]. The sequences of the forward and 
reverse primers were, respectively: 
TM3F 
TMR6R 
5'-CTGTGCGT(CG)ATCAGC(CA)T(CG)GAC(CA)- 
G(GC)TA-3' ;
5'-GAAAAAIGGGCACCA(GC)ATIAI(CA)(AG)I(AG)- 
AA-3'. 
The conditions of the PCR were as follows: after denaturation at
94°C for 4 min, 35 cycles (94°C, 55°C, 30 s; 72°C, 1 min) and an 
additional extension at 72°C for 4 min were carried out using a Per- 
kin-Elmer 9600 thermal cycler. Amplification reactions contained, ina 
total volume of 100/al, 0.3 ~tg human genomic DNA, 2.5 units Am- 
pliTaq polymerase (Perkin Elmer), 10 mM Tris-HCl (pH 8.4), 50 mM 
KC1, 1.5 mM MgC12, 3% DMSO, and 0.2 mM of each dATP, dCTP, 
dGTP, and dTTP. The amplified DNA fragments (400-700 base pairs 
long) were analyzed in a 1.5% agarose gel. Individual bands were 
excised, extracted with phenol, precipitated with ethanol, and 5% 
was used as template in a second PCR. The amplified DNA was 
analyzed on agarose gel and individual bands were subcloned into 
the PCRII vector (Invitrogen) for sequencing. Out of six bands ana- 
lyzed, one was found to have an unreported sequence of approxi- 
mately 410 bp insert that showed homology with G-protein-coupled 
receptors. This fragment was subsequently used to probe a human 
genomic DNA library as described elsewhere [17]. 
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2.3. Genomic DNA library screening and DNA sequencing 
A genomic DNA library prepared from placenta DNA partially 
digested with Sau3A restriction enzyme and subcloned into EMBL3 
sp6/t7 phage vector was purchased from Clontech Laboratories (Palo 
Alto, CA, USA). The library was plated and duplicate plaque lift 
filters were prepared according to standard protocols [14]. Approxi- 
mately 2 million recombinants were probed with the 410-bp PCR- 
generated fragment that was radiolabeled with [32p]dCTP by the ran- 
dom priming method. Plaques howing positive hybridization toboth 
filters were isolated and purified through two more rounds of screen- 
ing. Hybridization conditions and washing conditions were essentially 
the same as described previously [17]. 
2.4. Oligonucleotides, probes, labelling and hybridization analysis 
Oligonucleotides used for PCR and sequencing were synthesized on
an Applied Biosystems 392 DNA synthesizer. They were eluted from 
the column with a solution of 32% (v/v) ammonia for 60 min. The 
eluate was heated overnight at 55°C and oligodeoxynucleotides w re 
desalted by ethanol precipitation. The following oligonucleotides were 
used for PCR amplification reactions as well as for sequencing: 
p3 (5'-TGCTATGGACTCATGCTCGTCGCC-Y sense) 
p5 (5'-TCGGCCTGAAGAGTTTGACCACTA-Y sense) 
p6 (5'-GGCATCTGCCACCCACTTCGG-Y sense) 
p7 (5'-CCGAATTGGGTGGCAGATGCC-Y antisense) 
p4 (5'-CAGCTATGGTGCGGAGAGAGCGGA-Y antisense) 
p8 (5'-GTCGGAGGCGGAAGATGAAGAG-Y antisense) 
p9 (5'-GCCATGGCCAGTACAGAGTC-Y antisense). 
Probes used for genomic library screening (probe 1) as well as for 
Southern blot and Northern blot analysis (probe 2) were generated by 
PCR amplification using pOR3 DNA as a template with specific sets 
of primers flanking the indicated region. PCR conditions were as 
described [16]. Probe 1 corresponds to nucleotides 372-782 and was 
amplified using the primer set PI/P2. Probe 2 corresponds tonucleo- 
tide -3-196 and was amplified with primer set p8/p9. The amplified 
fragments were purified by agarose gel electrophoresis, labelled with 
[c~-32p]dCTP by the random priming method [15]. 
2.5. mRNA and genomic DNA analysis 
Human genomic DNA blots were purchased from Clontech La- 
boratories (Palo Alto, CA, USA). These blots are positively charged 
nylon membranes to which restriction enzyme digested genomic 
DNAs have been transferred by Southern blotting after being sepa- 
rated in a 0.8% agarose gel. Each lane contains 8 ~tg of genomic 
human kidney DNA. Prehybridization, hybridization conditions and 
washing conditions were performed at high stringency following the 
suppliers protocol. The filters were prehybridized for 4 h at 65°C in a 
solution containing 5 × SSPE, 10 × Denhardt's olution, 100 ~tg/ml 
freshly denatured, sheared salmon sperm DNA. SSPE (20 × ) = 3 M 
NaCI, 0.3 M Na3citrate'2H20, pH 7.0), Denhardt's solution 
(50x) = 5.0 g Ficoll (type 400, Pharmacia), 5.0 g polyvinylpyrroli- 
done (Sigma), 5.0 g bovine serum albumin in 500 ml. Hybridization 
was performed overnight at 65°C in the same buffer with probe 2. The 
filter was washed two times for 20 min each in solution A (2 × SSC, 
0.5% SDS) at 60°C, and three times for 15 min in solution B 
(0.1 ×SSC, 0.1% SDS) at 60°C. 
Multiple tissue Northern blots were purchased from Clontech La- 
boratories. Each lane contains approximately 2 gg of poly(A) + RNA 
from various human tissues, including heart, brain, placenta, lung, 
liver, skeletal muscle, kidney, and pancreas, pleen, thymus, prostate, 
testis, ovary, small intestine, colon, and peripheral blood leukocytes. 
RNA isolation, and construction of the blots, is described in the 
manufacturer's protocol. Hybridization was performed overnight at 
42°C in hybridization buffer (described in supplier's protocol). After 
hybridization, the filters were washed as indicated in the above men- 
tioned protocol. 
3. Results and discussion 
To isolate unknown genes that might encode novel mem- 
bers of the G-protein-coupled receptor family, we used poly- 
merase chain reaction amplification with highly degenerate 
oligonucleotide primers corresponding to conserved regions 
in the third and sixth transmembrane domains (TMDs) of 
previously cloned members of this family [17,18]. The PCR 
products were analyzed by gel electrophoresis in a 1.5% agar- 
ose gel and ethidium bromide staining. Amplified DNA frag- 
ments in the range of 0.44).6 kb were subcloned and charac- 
terized by sequence analysis. One of the clones contained a
410 bp insert of unreported sequence that encoded an amino 
acid sequence homologous to members of the G-protein- 
coupled receptors. The insert of this clone was radiolabelled 
and used to screen a human genomic DNA library at high 
stringency to isolate the complete gene. This process resulted 
in the isolation of a 16 kb human genomic DNA insert in 
EMBL lambda phage, designated pOR3. Southern blotting 
and restriction mapping showed the hybridizing region to be 
contained on a single 2.4 kb SacI fragment. Sequencing of this 
SacI fragment revealed an intronless open reading frame of 
1095 bp corresponding to a predicted 365 amino acid residue 
protein with an estimated molecular mass of approximately 41
kDa. Because of its structural resemblance with P2 purinocep- 
tors and its selective expression in pancreas (see below), the 
receptor cloned is hereafter referred to as P2P purinoceptor. 
The nucleotide sequence and the deduced amino acid se- 
quence of the P2P receptor are shown in Fig. 1. The open 
reading frame starts with an ATG initiator codon for transla- 
tion (nucleotides 1-3) that matches the consensus sequence for 
initiation of translation and the presence of an in-frame stop 
codon upstream of this methionine codon indicates that the 
clone encodes the entire coding region. A termination codon 
(nucleotides 1093-1095) occurs in-frame after the codon spe- 
cifying a leucine. The deduced amino acid sequence shares 
characteristic structural features with members of the G-pro- 
tein-coupled receptor family [18]. 
Hydrophobicity analysis of the predicted amino acid se- 
quence of P2P revealed the presence of seven stretches of hy- 
drophobic residues of about 25 amino acids, a feature shared 
by all members of the G-protein-coupled receptor family. The 
P2p purinoceptor also contains everal other structural fea- 
tures that are apparent in all members of the G-protein- 
coupled receptor family, including: (1) two cysteine residues 
(positions 109 and 185) in the first and second extracellular 
loop that are presumed to form a disulfide bond that poten- 
tially form a disulfide bridge that stabilizes the receptor con- 
formation; four proline residues within transmembrane re-
gions 4~7 (Pro 169, Pro 212, Pro 26°, and Pro 3°3) that may play 
crucial roles in helix arrangements and that are presumed to 
play a crucial role in ligand binding and transmembrane sig- 
nalling; and a conserved cysteine (Cys 32°) in the cytoplasmic 
tail distal to TM7 that may be modified by palmitoylation a d 
that could be used to anchor the tail to the plasma membrane 
[18]. 
A comparison of the deduced amino acid sequence of P2P 
with previously cloned G-protein-coupled receptors in the 
EMBL GenBank data base revealed the highest degree of 
sequence identity with the recently cloned P2u and P2Y pur- 
inoceptors (overall sequence identity: 50% and 30% respec- 
tively). Within the transmembrane domains the identity is 
even higher (71% with P2u and 49% with P2Y). A comparison 
of the predicted amino acid sequence of P2P with the recently 
cloned human P2u and P2Y receptors is schematically shown 
in Fig. 2. Furthermore, the dendrogram of several G-protein- 
coupled receptors hows the highest homology of the P2P 
receptor with the P2u purinoceptor (Fig. 3). 
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ctc tact t t t t t tgc tccagctcagggatgggggtgggcagggaaatcctgccaccctcact tc tcccct tcccatc tcca  -8 
ggggggc  ATGGCCAGTACAGAGTCCTCCC~I~TTGAGATCCCTAGGCCTCAGCCCAGGTCCTGGCAGCAGTGAGG~GAGC 73
M A S T E S S L L R S L G L S P G P G S S E V E 24 
| 7M!  .... 
TGGACTGTTGGTTTGATGAGGATTTCAAGTTCATC TGCTGCC TGTGAGCTATGCAGTTGTCTTTGTGCTGGGCTTGGGCC 154 
L D C W F D E D F K F I L L P V S Y A V V F V L G L G 51 
! ! 
TTAACGCCCCAACCCTATGGCTCTTCATCTTCCGCCTCCGACCCTGGGATGCAACGGCCACCTACATGTTCCACCTGGCAT 235 
L N A P T L W L F I F R L R P W D A T A T Y M F H L A 78 
TM n I 
TGTCAGACACC~TA'I~TGC~TCGCTGCCCACCCTCATCTACTATTATGCAGCCCACAACCACTGGCCCTTTGGCAC'I~ 316 
L S D T L Y V L S L P T L I Y Y Y A A H N H W P F G T 105 
I TM III | 
AGATCTGCAAGTTCGTCCGCTTTCTTTTCTATTGGAACCTCTACTGCAGTGTCCTTTTCCTCACCTGCATCAGCGTGCACC 397 
E I C K F V R F L F Y W N L Y C S V L F L T C I S V H 132 
! 
GCTACCTGGGCATCTGCCACCCACTTCGGGCACTACGCTGGGGCCGCCCTCGCCTCGCAGGCCTTCTCTGCCTGGCAGTTT 478 
R Y L G I C H P L R A L R W G R P R L A G L L C L A V 159 
TM IV I 
GGTTGGTCGTAGCCGGCTGCCTCGTGCCCAACCTGTTCTTTGTCACAACCAGCAACAAAGGGACCACCGTCCTGTGCCATG 559 
W L V V A G C L V P N L F F V T T S N K G T T V L C H 186 
| TMV 
ACACCACTCGGCCTGAAGAGTTTGACCACTATGTGCACTTCAGCTCGGCGGTCATGGGGCTGCTCTTTGGCGTGCCCTGCC 640 
D T T R P E E F D H Y V H F S S A V M G L L F G V P C 213 
! 
TG•TcA•T•TTGTTTGcTATGGA•T•ATGG•TcGT••••TGTAT•AG•••TTGc•A•G•TcT••AcAGT•GT•TT•T•G•c  721 
L V T L V C Y G L M A R R L Y Q P L P G S A Q S S  S R  240 
| TM VI 
TC CGCTC TCTCC GCAC CATAGCTGTGGTGCI"~AC TC"TC T'IWGC TGTCTGC TTCGTGC CT'l~r CCACATCAC CC GCAC CA'lvFr 802 
L R S L R T I A V V L T V F A V C F V P F H I T R T I 267 
ACTACCTGGC CAGGC TGTTGGAAGC TGAC TGCCGAGTACTGAACATTGTCAACGTGGTCTATAAAGTGACTCGGCCCC TGG 883 
Y Y L A R L L E A D C R V L N I V N V V Y K V T R P L 294 
, TMVI I  | 
CCAGTGCCAACAGCTGCCTGGA•CCTGTG•TCTACTTG•TCACTGGGGACAAATATCGACGTCAGCT•CGT•AGCTCTGTG 964 
A S A N S C L D P V L Y L n T G D K Y R R Q L R Q L C 321 
G~GTGGCAAGC~CCAGC~C~G~A~GGCTG~CTCTTC~CTGGCACTAGTGT~C~TGC~TGAGGATAG~AGCTGCAGG'1X2~GG 045 
G G G K P Q P R T A A S S L A L V S L P E D S S C R W 348 
CGGCCACCC•C•AGGACAGTAG•TGCT•TA•T•CTAGGGCAGATAGATTGTAAcacgggaagccgggaagtgagagaaaag 1126 
A A T P Q D S S C S T P R A D R L - 365  
gggatgagtgcagggca  
Fig. 1. Restriction map and nucleic acid sequence of clone pOR5 (P2 purinoceptor). Top, the map depicts a portion of clone pOR5, with the 
5' end of the sense strand to the left and the coding region boxed. Relevant restriction enzymes are marked. Bottom, nucleotide sequence of 
the human P2P purinoceptor gene. The DNA sequence is numbered at the right, beginning with the translation initiation codon. The amino 
acid numbering is indicated below the nucleotide numbering. The positions of the putative transmembrane regions (I-VII) are depicted by lines 
above the nucleotide sequence. The nucleotide sequence of the human P2P purinoceptor has been submitted to the Genbank/European Molecu- 
lar Biology Lab database under acquisition umber X96597. 
Several interesting structural features that are apparent for 
the P2u and P2Y purinoceptors are also conserved in the 
cloned P2P receptor: whilst most of the G-protein-coupled 
receptors contain an aspartic acid (DRY) at the interface 
between TMR3 and the second cytoplasmic loop [18], this 
aspartic acid is replaced by an histidine (HRY) in both P2u, 
P~y, and P2P purinoceptors [7]. Also worth noting is the pre- 
sence of two arginines (position Arg 265 and Arg 292) as well as 
a histidine (His 262) in transmembrane r gion VI and VII in the 
P2P purinoceptor, at the same relative position as was found 
in the human P2v and Pzv purinoceptors (reviewed in [7]). 
Moreover, using site directed mutagenesis techniques it was 
recently shown that these conserved positively charged amino 
acids in the P~u purinoceptor are involved in the binding of 
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the negatively charged phosphates of ATP and UTP ligands 
[19]. Thus, on the basis of the high degree of sequence homol- 
ogy with the P2u and P2v purinoceptors, as well as the con- 
servation of several key residues presumed to be involved in 
binding of nucleotides it is highly likely that the cloned P2P 
receptor gene encodes a new member of the purinoceptor 
family. 
To determine the number of genes encoding the P2P recep- 
tor, human genomic DNA was digested with several different 
restriction enzymes, separated on 0.8% agarose, transferred to 
nylon filters and hybridized using a specific probe for the P2P 
receptor (Fig. 5). Under high stringency conditions, single 
hybridizing bands were obtained in all lanes suggesting that 
P2v is a singly copy gene. 
Northern blot analysis was performed to investigate the 
expression of the P2P purinoceptor in human tissues. As 
shown in Fig. 4, a single prominent mRNA species of ap- 
proximately 2.6 kb, was detected in pancreas, despite the 
fact that a relatively small amount of RNA was transferred 
to this lane, as visualized by the actin hybzidisation. No evi- 
dence for expression was found in any other tissue examined, 
including: heart, brain, placenta, lung, liver, skeletal muscle, 
kidney, spleen, thymus, prostate, testis, ovary, small intestine, 
colon and peripheral blood leukocytes. 
One striking feature that discriminates the P2P purinoceptor 
from the P2u and P2P purinoceptors i  its tissue distribution. 
Whereas the P2u and P2v purinoceptors are widely distributed 
throughout the periphery and the CNS [10-12], the P2P pur- 
inoceptor is exclusively expressed in pancreas. Its unique tis- 
sue distribution is especially of interest in the light of several 
studies that showed profound effects of ADP nucleotides on 
insulin secretion [5,6,21,22]. In these studies it has been pro- 
P2Y  MTEVLWPAVPNGTDAAFLAGPGS SWGNSTVASTAAVS S SFKCALTKTGFQFY 52 
P2U MA . . . . . . . . .  ADLGP . . . . . . . .  WNDT I NGTWDGDELGYRC RF  - NEDF KYV 34 
P2P  MA . . . . . . . . .  STESSLL  . . . . . .  RSLGLS PGPGS S EVELDCWF - DEDFKF  I 36 
~ ]  [Imm 
P2Y  yL  PAVY ILVF  I IGFLGNSVAIWMFVFHMKPWSGI  SVYMFNLALADFLYVLTL  104 
P2U LL  PVSYGVVCVLGLCLNAVGLY I  FLCRLKTWNASTTYMFHLAVSDALYAASL  86 
P2P  LL  PVSYAVVFgLGLGLNAPTLWLF I FRLRPWDATATYMFHLAL  SDTLYVLSL  88 
Ill 
P2Y  PAL l  FYYFNKTDWI  FGDAMCKLQRF I  FHVNLY-  G I LFLTC I SAHRYSGVVYP 155 
P2U PLLVYYYARGDHWPFSTVLCKLVRFLFYTNLYC S I LFLTC I SVHRCLGi rLRP  138 
P2P  PTL  IYYYAAHNHWPFGTE ICKFVRFLFYWNLYC SVLFLTC I SVHRYLGI  CHP 140  
IV 
P2Y  LKSLGRLKKKNAIC  I SVLVWL IVVVAI  S P I LFYSGTGVRKNKTI  TCYDTTSD 207 
P2U LRSLRWGRARYARRVAGAVWVLVLACQAPVLYFVTTSAR-  GP  - LTCHDTSAP 188 
P2P  LRALRWGRP RLAGLLC LAVWLVVAG C LVPNL  F FVTT  S NK - GTT I rLCHDTTR P 191 
* . . *  . . . . .  * * . . *  * *.. * . . . .  * . ** .  
V 
P2Y  EYLRSYF  IYSMCTTVAMFCVPLVL I  LGCYGL IVRAL  IYKDL  . . . . .  DNSPLR 254 
P2U ELFSRFVAYS SVMLGLLFAVPFAVI  LVCYVLMARRL - LKPAYGTSGGL PRAK 239 
P2P  EEFDHYVHF S SAVMGLLFGVPCLVTLVCYGLMARRL -YQPLPGSAQSS SRLR 242 
Vl 
P2Y  RKS IYLV I  IVLTVFAVSY I  PFHVMKTMNLRAR-  LDFQTPAMCAFNDRVYAT~ 305 
P2U RKSVRTIAWLAVFALC FLPFHVTRTLYYSFRSLDLS . . . .  CHTLNAINMAY 287 
P2P  - - SLRT IAVArLTVFAVC FVPFHITRT  IYYLARLLEAD . . . .  CRVLNIVNVVY 288 
Vn  
P2Y  QVTRGLASLNSCVDPILYFLAGDT - - - FRRRL  SKAT . . . .  RKASRRSEANLQ 350 
P2U KVTR-  LASANSCLDPVLYFLAGQRLVRFARDAKPPTGPSPATPARRTLGLRR 338 
P2P  KVTRPLASANSCLDPVLYLLTGDK-  - -YRRQLRQLCGGGKPQ P . . . . . . . .  R 329  
P2Y  SKSEDMTL-  -N ILPEFKQ . . . . . . . . . . . . . .  NGDTSL  372 
P2U SDRTDMQRIGDVLGS SEDSRRTESTPAGS - ENTKDI  RL  375  
P2 P TAASSLALVS - - L PEDS SCRWAATPQDSSCSTPRADRL 365  
Fig. 2. Comparison of the pOR5 (P2P purinoceptor), the human 
P2u and P2v purinoceptor deduced amino acid sequences. The seven 
putative transmembrane domains (I-VII) are indicated above the 
amino acid sequence. Gaps have been introduced to maximize align- 
ment. Residues that are identical in the alignment of P2P, P2u, and 
P2Y purinoceptors are labelled with a '*' below the sequence. Resi- 
dues labelled with a '°' below the sequence indicate conserved resi- 
dues. 
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Fig. 3. Dendrogram of several G-protein-coupled receptors, achieved 
by the method of average linkage cluster analysis using the PC/ 
Gene, CLUSTAL program [20], shows the most similar sequences 
besides each other. The shown distances are inversely proportional 
to the sequence homology. AD-A1 R., AD-A2a R. and AD-A3 R. 
are the adenosine receptors A1, A2 and A3, respectively. P2Y and 
P2U are the recently cloned purinoceptors. 
posed that the effects of ADP analogues on insulin secretion 
are mediated by a P2 purinoceptor. The finding of a P2P 
purinoceptor which is exclusively expressed in pancreas makes 
it attractive to speculate that the reported effects of ADP 
analogues on insulin secretion are mediated through the pre- 
sently identified receptor. In view of this, it will be important 
to determine the precise anatomical distribution of the P2P 
purinoceptor within the pancreas, e.g. via in situ hybridiza- 
tion, to see whether it is expressed in the [3-cells of the pan- 
creas. Furthermore, it will be important to determine whether 
the pharmacological profile of the cloned receptor is similar to 
that of the previously identified pancreas receptor. To this 
end, experiments are aimed to express the cloned gene in eu- 
karyotic host cells, lacking endogenous P2 purinoceptors. In 
case the purinoceptor described here indeed plays a role in the 
secretion of insulin it may be a target for new antidiabetic 
drugs. 
4. Note added in proof 
During the submission of the manuscript a clone with a 
similar sequence was reported by Communi et al., J. Biol. 
Chem. 270 (1995) 30849. 
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